Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Father and son spending Christmas together after health scares - 2From Specialist to Proficient Picture taker: Individual Triumphs
- 3UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- 4Vote in favor of the bloom plan that adds a bit of excellence to your life!
- 5Data centers in space: Will 2027 really be the year AI goes to orbit?
- How did birds survive while dinosaurs went extinct?
- PA accuses Israel of 'human trafficking' after planeload of Gazans arrives in South Africa
- New hybrid mpox strain discovered in UK after US reports local spread
- Most loved Well known Accessory Styles For 2024
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- Becoming amazing at Arranging Pay Raises
- Visiting This Japanese City Just Got A Little More Expensive (Here's What Travelers Should Know)
- 10 High priority Contraptions for Tech Aficionados
- 6 Solid Vehicle Fix Administrations to Keep Your Vehicle in Prime Condition
